XtalPi and Laboratoires Pierre Fabre have entered a strategic partnership to accelerate drug discovery in oncology and other therapeutic areas using AI and robotics, with undisclosed financial terms.
XtalPi announces an AI-driven drug discovery collaboration with Laboratoires Pierre Fabre covering oncology, possibly dermatology and rare diseases. The deal includes an upfront payment, milestone payments and an economic interest, but no financial terms were disclosed, so the revenue impact cannot be quantified. As a routine partnership without figures, the effect is limited, though the recurring AI pharma services theme may mildly support sentiment.
Laboratoires Pierre Fabre and XtalPi Holdings (2228.HK) announced a collaboration on November 9, 2026, to develop novel small-molecule drug candidates. The partnership focuses on oncology, dermatology, and rare diseases, utilizing XtalPi's AI and robotics platform to identify candidates for Pierre Fabre's clinical development pipeline.
The agreement includes an upfront payment, several milestone payments and a later economic participation, but the specific financial terms were not disclosed.
XtalPi will use its AI capabilities and robotics platform to design novel small-molecule drug candidates from scratch, while Pierre Fabre handles later clinical and commercial development.